AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01597362 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field.
Study NCT01597362 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopy
Description: A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
Study NCT03121690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone 40 mg/day for 7 days
Study NCT03121690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 5ml saline / day for 7 days
Study NCT02593539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemiralisib
Description: Participants will be administered nemiralisib
Study NCT04091906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cell apheresis
Description: Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
Study NCT03396731 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: geko™ medical device
Description: The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
Study NCT04856761 — intervention group
Intervention type: DRUG
Intervention: S-1
Description: S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
Study NCT04856761 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
Study NCT01748383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of BMMCs
Description: The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
Study NCT01748383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of CD 133+ cells
Description: The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
Study NCT01748383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stenting of IRA
Description: The only stent implantation
Study NCT02609399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oral
Study NCT02609399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician.
Study NCT00404729 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Citicoline
Description: Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
Study NCT03895138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Glucommander Protocol (SGP)
Description: Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
Study NCT03895138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Glucommander (OGM)
Description: The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
Study NCT00302640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alinia (nitazoxanide)
Study NCT00302640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alinia (nitazoxanide)
Study NCT01390168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-administrated CBT-Treatment
Description: This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
Study NCT01390168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: active waitlist
Study NCT03289390 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
Study NCT01490203 — intervention group
Intervention type: DRUG
Intervention: Gd-EOB-DTPA
Description: 1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.
Study NCT01490203 — intervention group
Intervention type: DRUG
Intervention: Gd-EOB-DTPA
Description: 1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion.
Study NCT01490203 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: 1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.
Study NCT01490203 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: 1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection.
Study NCT05261217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The motion 3D II appliance
Description: The motion 3D II appliance treating class II malocclusion
Study NCT00245063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Optional correlative studies
Study NCT02339649 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Sample
Description: Blood Sample
Study NCT02339649 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurocognitive Assessment
Description: Neurocognitive Assessment
Study NCT04630054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask
Description: Intervention individuals will be given cloth or surgical face masks.
Study NCT04630054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face mask awareness
Description: Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
Study NCT02812004 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultra Q Reflex YAG laser (Ellex)
Description: Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses.
Study NCT02812004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra Q Reflex YAG laser (Ellex)
Description: Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses.
Study NCT04756544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175
Description: probiotic
Study NCT04756544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00839111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Sorafenib 400mg twice daily from d3 to d14,d17-28
Study NCT00839111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
Study NCT03582358 — intervention group
Intervention type: OTHER
Intervention: Food weighing
Description: Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
Study NCT01729689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo cognitive behavioral therapy
Study NCT01729689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01729689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02049502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biologically active human fecal microbiota
Description: instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
Study NCT02049502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sigmoidoscopy
Study NCT04176861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home-based Brainwave Entrainment Technology
Description: Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights
Study NCT03449888 — intervention group
Intervention type: PROCEDURE
Intervention: Regadenoson myocardial perfusion imaging stress test
Description: Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
Study NCT03449888 — intervention group
Intervention type: PROCEDURE
Intervention: Arm exercise electrocardiographic stress test
Description: Published arm exercise score and best fit model of arm exercise ECG stress testing data.
Study NCT03449888 — intervention group
Intervention type: PROCEDURE
Intervention: Treadmill electrocardiographic stress test
Description: Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
Study NCT03449888 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary artery calcium score and cardiac computed tomographic angiography
Description: Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease > 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
Study NCT04358393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: APG-115 given once daily on day 1-5 of every 28 day cycle
Study NCT04358393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacitidine
Description: 5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
Study NCT01849133 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external fractionated radiotherapy
Description: conventional external beam radiotherapy
Study NCT01849133 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
Study NCT02053688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astigmatic Correction Lens (Nexis ACCL lenses)
Description: Astigmatic refractive error correction
Study NCT02053688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toric Soft Contact Lenses
Description: astigmatism correction using toric optics
Study NCT01312194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal therapy in one visit
Description: Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
Study NCT01312194 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Canal Therapy in two-vist
Description: The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
Study NCT00403104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2506PO
Description: 1200 mg QD / 18 months
Study NCT00403104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-2506PO
Description: 0 mg QD / 18 months
Study NCT03031561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo standard ultrasound
Study NCT03031561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicoPure ultrasound
Description: Undergo MicoPure ultrasound
Study NCT03031561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Breast
Description: Undergo breast biopsy or surgical resection
Study NCT02339649 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resting State EEG
Description: 10-20 Minutes of Resting State EEG
Study NCT02858479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: stimulation on painful area (area allodynic)
Description: these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds
Study NCT02858479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: same stimulation on non-painful area
Description: these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds
Study NCT02858479 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MRI scan
Description: 2 sessions for 10 minutes :~* 11 controls stimulations for 6 s each spaced 20 s without stimulation.~* 11 allodynic stimulations for 6 s each spaced 20 s without stimulation.
Study NCT01217281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Mouth Non-Surgical Periodontal Therapy
Description: Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
Study NCT01305915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Getting Back on Track
Description: The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
Study NCT01328873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiological analysis
Description: Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
Study NCT00584662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline Hydrochloride
Description: Oxymetazoline Hydrochloride TWO SPRAYS BID
Study NCT02291159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DNHS ® (Dry Needling for Hypertonia and Spasticity)
Description: Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
Study NCT02291159 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
Study NCT02495363 — intervention group
Intervention type: PROCEDURE
Intervention: PECS Block
Description: As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11
Study NCT02495363 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine 0.25-0.5%
Description: Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11
Study NCT04226352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan will be administered and its tolerability evaluated.
Study NCT01658800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX161C vaccine
Description: Recombinant H5 influenza vaccine, VAX161C
Study NCT02587494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac catheterization
Description: Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
Study NCT01656239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fedovapagon 1 mg
Study NCT01656239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fedovapagon 2 mg
Study NCT01656239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fedovapagon 4 mg
Study NCT01656239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ( sugar pill)
Study NCT00986336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
Study NCT00986336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 2-100 mg tablets twice daily for 2 weeks (400 mg/day)
Study NCT00986336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Twice daily, individualized dosing to stabilization at 1-6 mg/day.
Study NCT00986336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topiramate
Description: 2-25 mg tablets twice daily for 2 weeks (100 mg/day)
Study NCT04761185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed in HIPEC
Study NCT02593370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-epinephrine added gadoterate meglumine
Study NCT02593370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-epinephrine added gadoterate meglumine